论文部分内容阅读
目的探讨米力农治疗小儿充血性心力衰竭(CHF)的疗效及安全性。方法研究对象为广西壮族自治区人民医院2004—2006收治的40例CHF患儿,随机分为A、B二组。A组20例为米力农组,米力农剂量为0.5μg/(kg.min),B组20例为多巴胺组,剂量均为5μg/(kg.min),各组持续给药5d,观察维持量的米力农临床疗效和心功能指标的变化,并与多巴胺组进行比较。结果米力农组用药3～5d后,临床症状、体征及心功能指标均有显著改善(P<0.05),总有效率95.0%;多巴胺组临床有效率仅为75.0%,治疗前后心功能指标改善不明显(P>0.05);A、B两组治疗后临床疗效和心功能指标比较有统计学意义(P<0.05)。而血、尿常规,肝、肾功能及血小板计数均无异常,心电图无改变,心率、血压无显著变化(P>0.05),无严重心律失常的发生。结论维持量的米力农治疗小儿CHF是安全、有效的,其疗效优于多巴胺。
Objective To investigate the efficacy and safety of milrinone in the treatment of children with congestive heart failure (CHF). Methods The subjects were 40 CHF children admitted to the People’s Hospital of Guangxi Zhuang Autonomous Region from 2004 to 2006 and were randomly divided into two groups. 20 cases in group A were milrinone, the dose of milrinone was 0.5μg / (kg · min), 20 cases in group B were treated with dopamine, the dosage was 5μg / (kg · min) To observe the maintenance of the amount of clinical efficacy of milrinone and cardiac function changes, and compared with the dopamine group. Results After 3 to 5 days, the clinical symptoms, signs and cardiac function indexes of Milrinone group were significantly improved (P <0.05), the total effective rate was 95.0%. The clinical effective rate was only 75.0% in the dopamine group. Before and after treatment, (P> 0.05). The clinical curative effect and cardiac function index of A and B groups after treatment were statistically significant (P <0.05). The blood, urine, liver and kidney function and platelet count were normal, no changes in ECG, heart rate, blood pressure no significant change (P> 0.05), no serious arrhythmia. Conclusion The maintenance dose of milrinone is safe and effective in children with CHF, and its efficacy is superior to that of dopamine.